Compare Enveric Biosciences Inc (ENVB) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Corning Incorporated — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Corning Incorporated trades at $157.28 (market cap $140.62B). The key difference: Corning Incorporated is far larger — about 21019.4× Enveric Biosciences Inc's market cap, and Corning Incorporated pays a 0.69% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Corning Incorporated for 35 Days on average.
| ENVB | GLW | |
|---|---|---|
Market Cap | $6.69M | $140.62B |
Volume | 41,141 | 5,163,560 |
Sector | Health | Technology |
52-Week High | $10.80 | $255.79 |
52-Week Low | $1.27 | $78.03 |
Typical Hold Time | 14 Days | 35 Days |
Enterprise Value | -$1.60M | $147.50B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Corning (GLW) trades at $152.81, down 9.57% despite recent positive catalysts including a $3B AT&T fiber supply agreement. The stock shows strong fundamentals with revenue growth from $13.1B to $15.6B in 2025 and net income surging to $1.6B. Technical indicators show bullish momentum with the current price below key resistance levels. Analyst consensus remains positive with 57% buy ratings and a $171.25 price target representing 12% upside potential.
GLW presents a compelling opportunity driven by AI infrastructure demand and the AT&T partnership, though elevated valuation metrics (P/E 75.23) and ongoing patent litigation create near-term headwinds. The company's strong cash flow generation and dividend payments support shareholder returns while expansion in fiber optics positions it for sustained growth in the connectivity ecosystem.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
